You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Morphology-Based Rating of Egg Development Potential

    SBC: CAMBRIDGE RESEARCH AND INSTRUMENTATION            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this Phase II project is to develop a more effective tool for assessing the development potential of human oocytes and to reduce the emotional, health, and financial costs of low IVF success rates, presently approximately 25% per cycle. To compensate for these low rates, as many as three or more embryos are transferred to the mother-this practi ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Active Bottle for Preterm Infant Oral Feeding

    SBC: Infoscitex Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Of approximately 4 million live births in the U.S. in year 2000, 11.6 percent or about 471,000 infants were born less than 37 weeks gestation (Martin et al). Preterm infants may spend days or weeks in a neonatal intensive care unit (NICU), where they are nutritionally supported by nasogastric feeding tube, until they are capable of oral feeding by means of ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Improved yield of human albumin from transgenic cow milk

    SBC: GTC BIOTHERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this program is to provide an abundant, cost-effective, biosecure source of human albumin for human therapeutic use by producing recombinant human albumin (rhA) in the milk of transgenic cows. Human albumin is isolated from donated human plasma, but shifts in the plasma fractionation industry, concerns about cost and anxiety about blood saf ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Synthesis and Evaluation of a Novel Anti-HIV Agent

    SBC: Kucera Pharmaceutical Company            Topic: N/A

    The long-term goal of this research is to develop a drug that is safe and effective against drug-resistant human immunodeficiency virus (HIV) infection. Several challenges confront current anti-HIV chemotherapy. The frequency of drug-resistant and multidrug-resistant HIV-1 is increasing. Toxicities associated with current HIV medications often result in the discontinuation of these therapies. Phys ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. SOD/Catalase mimics for age-related learning impairment

    SBC: Proteome Systems, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Aging is often accompanied by a deterioration of learning and memory processes, a condition now referred to as mild cognitive impairment (MCI). Recent studies have indicated that 12% of patients afflicted with MCI will develop Alzheimer's disease, as opposed to 2% of the general population. Although the causes underlying MCI are not known, there is much evidenc ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. SOD/Catalase mimics for age-related learning impairment

    SBC: Proteome Systems, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Aging is often accompanied by a deterioration of learning and memory processes, a condition now referred to as mild cognitive impairment (MCI). Recent studies have indicated that 12% of patients afflicted with MCI will develop Alzheimer's disease, as opposed to 2% of the general population. Although the causes underlying MCI are not known, there is much evidenc ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Imaging system for in vivo fluorescence quantification

    SBC: Visen Medical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Several small-animal reflectance optical imaging systems are offered commercially for qualitative observations of surface fluorescence in tissues. However, no commercial small animal or clinical imaging system that enables quantification of fluorochromes in highly scattering media such as biological tissue exists. The overall goal of the current proposal is ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Immunoaffinity Isolation of Phosphopeptides

    SBC: CELL SIGNALING TECHNOLOGY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Among post-translational modifications, protein phosphorylation is particularly relevant to cancer biology and therapy. However, despite advances in proteomics, it is still difficult to pinpoint phosphorylation sites in proteins. The long-term goal of this project is to develop and commercialize a multiplexed method for isolating, identifying, and quantifying ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. DNA Polymerase IIIe, A New Antibiotic Target

    SBC: GLSynthesis Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): In phase I we have identified a new class of active-site directed inhibitors of DMA polymerase HIE, a novel replicative enzyme in Gram+ bacteria. The compounds, 7-substituted-N2-(3,4-dichlorobenzyl)guanines "DCBGs", are potent enzyme inhibitors, and selected derivatives have potent and broad activity against clinically relevant Gram+ bacteria. We have identifi ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government